menu

TAG: HUMMINGBIRD DIAGNOSTICS

Hummingbird Diagnostics Developing miRNA-Based Immunotherapy Predictor on Heels of Positive Study

Apr 07, 2022 | Molika Ashford NEW YORK – New research published last week by scientists from Germany’s Hummingbird Diagnostics and collaborators suggests that blood-borne microRNAs (miRNAs) may enable better personalization of cancer immunotherapy. In the study, appearing in the Nature partner journal Precision Oncology, the investigators used whole-blood miRNA profiling to develop a five-miRNA risk score that is predictive of overall survival in stage IV non-small cell lung cancer patients following immunotherapy — outperforming PD-L1 expression, which is currently the most established biomarker for guiding the use of anti-PD-1 agents. Hummingbird now hopes to commercialize a test based on this biomarker signature to guide immunotherapy in lung...

READ MORE
Blood-based microRNA signature may predict survival in immunotherapy-treated NSCLC

 March 31, 2022 A blood-based signature of five microRNAs demonstrated the ability to predict OS of patients with lung cancer receiving immunotherapy and stratify them for treatment, according to a study published in npjPrecision Oncology.  Researchers reported that because the signature appears to work from a single timepoint before treatment, it differs from classical circulating tumor DNA-based assays, where blood at baseline is typically dynamically compared with follow-up samples. “Importantly, the signature does not require any prior tumor tissue analysis and could be used in an ‘off-the-shelf’ manner,” Bruno R. Steinkraus, PhD, chief scientific officer at Hummingbird Diagnostics, told Healio. “We believe our test could...

READ MORE
Hummingbird Diagnostics Announces Publication of Study on the Utility of miRisk, a Blood-based microRNA Analysis, to Predict Overall Survival for Advanced Non-Small Cell Lung Cancer in npj Precision Oncology

—Results describe development of analysis to uncover association of several microRNAs with overall survival following initiation of immunotherapy— —Blood-based test holds potential for broad applicability for the management of patients with cancer—March 31, 2022 05:00 AM Eastern Daylight Time  March 31, 2022 05:00 AM Eastern Daylight Time  HEIDELBERG, Germany–(BUSINESS WIRE)–Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced the publication of a study in the journal npj Precision Oncology that describes the discovery and validation of miRisk, a first-of-its-kind microRNA (miRNA) biomarker signature that offers the prospect of a blood-based companion diagnostic...

READ MORE
JÖRG DEBATIN TO CHAIR THE SUPERVISORY BOARD OF HUMMINGBIRD DIAGNOSTICS GMBH International healthcare leader strengthens miRNA experts

HEIDELBERG, BOSTON, October 9, 2018 – Hummingbird Diagnostics GmbH today announced that Prof. Dr. med. Jörg Debatin is appointed Chairman of the Supervisory Board with immediate effect. The former Vice President and Chief Technology Officer of GE Healthcare and CEO of Amedes AG directed the University Hospital Hamburg-Eppendorf for 8 years as its Medical Director and CEO. He started his professional career as a diagnostic radiologist at the University Hospitals of Duke, Stanford and Zürich (Switzerland). In 1999, he was appointed Professor of Diagnostic Radiology at the University of Essen. Debatin has studied medicine at the University of Heidelberg and holds...

READ MORE
BGI, Hummingbird Diagnostics to Develop miRNA Tests for Neurodegenerative Disorders

Dec 06, 2017 | staff reporter NEW YORK (GenomeWeb) – BGI of China and Hummingbird Diagnostics of Germany have signed a memorandum of understanding to collaborate on miRNA-based molecular diagnostic applications using next-generation sequencing technology, in particular in the areas of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Under the agreement, the partners will use Hummingbird’s miRNA database and expertise in sample preparation as well as BGI’s BGISEQ sequencer and analysis pipeline to develop targeted miRNA in vitro diagnostic assays for Alzheimer’s, Parkinson’s, and other diseases. In addition, the firms will collaborate in the areas of wellness, fitness, and...

READ MORE
Hummingbird Diagnostics GmbH and Saarland University Collaborate in Early Disease Detection Based on Molecular Markers: miRNA Experts Sign Framework Agreement

HEIDELBERG and SAARBRÜCKEN, November 14, 2017 – Hummingbird Diagnostics GmbH, specialized in early disease detection using molecular markers derived from blood, and Saarland University agreed on a comprehensive framework agreement regarding an expanded collaboration in the field of molecular diagnostics. The work aims at the validation of miRNA biomarkers in blood samples, allowing for an early detection of common serious diseases including lung cancer, chronic obstructive lung disease (COPD), Alzheimer’s and Parkinson’s. The project partners at Saarland University are the Department of Human Genetics and the Chair of Clinical Bioinformatics. Hummingbird Diagnostics has been maintaining long-standing research collaborations with both...

READ MORE
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER